Abstract: Abstract: Objective To compare the effects of micafungin and fluconazole in preventing early invasive fungal disease (FID) in patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Methods Data of 82 Allo-HSCT patients were retrospectively analyzed. The observation group (n=42) was given intravenous micafungin until the leukocytes were stable after implantation, and the rest time was given fluconazole. The control group (n=40) was given the oral fluconazole. The patients were followed up to 100 days after transplantation. The incidence of IFD and adverse drug reactions were compared between the two groups. Results The incidence of IFD was 7.1% (3 cases) in the observation group and 22.5% (9 cases) in the control group, the difference was statistically significant (χ2 =3.868, P＜0.05). Drug-related adverse reactions were 11.9% (5 cases) vs. 15.0% (6 cases) in the two groups, and there was no significant difference between two groups (χ2patients and those without ATG (P＞0.05). Conclusion Micafungin combined with fluconazole can effectively reduce the incidence of IFD in the early stage of Allo-HSCT patients, and without incensement of adverse drug reactions. =0.169, P＞0.05). There was no significant difference in the incidence of IFD between the two groups of ATG

Key words: antifungal agents, fluconazole, hematopoietic stem cell transplantation, mycoses, micafungin